![Dirk Weber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Storia della carriera di Dirk Weber
Precedenti posizioni note di Dirk Weber
Società | Posizione | Inizio | Fine |
---|---|---|---|
Aurealis Oy
![]() Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | Direttore Tecnico/Scientifico/R&S | 01/01/2010 | 01/06/2019 |
Fondatore | 01/01/2010 | 01/06/2019 | |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Direttore Tecnico/Scientifico/R&S | 01/01/2014 | - |
Fondatore | 01/01/2014 | - |
Statistiche
Distribuzione geografica
Finlandia | 2 |
Svizzera | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Settori
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Aurealis Oy
![]() Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | Health Technology |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Dirk Weber
- Esperienza